

Vantage Esmo 2020 roundup



Jacob Plieth



Here's a round up of Vantage's coverage of the 2020 European Society for Medical Oncology congress.

September 24

[Esmo 2020 movers - antibody drug conjugates dominate the news flow](#)

Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.

September 23

[J&J goes for broke with lung cancer bispecific](#)

The company's EGFR and cMet targeted bispecific has generated early but encouraging signals in lung cancer - however, J&J faces stiff competition.

[Can Alkermes succeed where Nektar failed?](#)

Early signs suggest that Alkermes might have found a therapeutic window with its IL-2-targeting agent, ALKS 4230.

September 22

[More encouraging signs for checkpoint bispecifics](#)

Promising but early data on PD-1 x CTLA-4 bispecifics from MacroGenics and Akeso add further weight to this approach.

September 21

[Double win complicates the gastric cancer picture](#)

Bristol Myers Squibb and Merck & Co hail front-line successes, but histology and biomarker status will remain live issues for doctors.

[Some backing for Beigene's unusual combo approach](#)

The company is one of very few to have studied combining PD-1 and PD-L1 blockade, an approach still in need of scientific validation.

[Modest early activity for a Jounce competitor](#)

[Europeans unimpressed with Lynparza's prostate performance](#)

September 20

[Lilly's latecomer scores in early breast cancer](#)

Verzenio looks set to move into a valuable adjuvant setting as Pfizer's miss with Ibrance is laid bare.

[Kras cools off](#)

A long-awaited update from Amgen's Kras inhibitor shows waning single-agent efficacy – a situation apparently pre-empted by Mirati.

[Pfizer's next-gen lung cancer drug impresses](#)

September 19

[Agenus sees light at the end of the tunnel at last](#)

A benefit for balstilimab in cervical cancer irrespective of PD-L1 expression gives Agenus a shot at US approval.

[Opdivo and Cabometyx are back in the game](#)

Full data from the Checkmate-9ER trial suggest a new combo to match Merck & Co's Keytruda plus Inlyta in first-line renal cancer.

September 18

[Ipatasertib Akts up](#)

A miss for Roche's Akt inhibitor in advanced breast cancer leaves questions over population and combination.

[Mediola makes a case for triplet therapy in ovarian cancer](#)

[Private group claims early but impressive pancreatic win](#)

September 17

[Mersana holds steady in ovarian cancer](#)

Expectations grow with more data on XMT-1536, but durability is still a key question.

September 11

[Kidney cancer showdown gets star billing \(preview\)](#)

[Late-breaking immunotherapy \(preview\)](#)

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

© Copyright 2023 Evaluate Ltd.